Background: Coronavirus disease 2019 (COVID-19) has the possibility of activating systemic coagulation, leads to hypercoagulability condition and caused venous thromboembolism (VTE). Risk stratification measures hypercoagulability in COVID-19 to treat patients. Common coagulopathy laboratory findings in COVID-19 were changes in D-Dimer, prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombocyte, and fibrinogen level.

Aims: This research wants to see the difference in the value of the coagulopathy screening examination between medium-high and low-risk VTE groups in COVID-19 patients.

Methods: Cross-sectional analytical observation done on confirmed COVID-19 patients. The risk assessment of VTE was assessed with IMPROVE score. Coagulopathy screening tests performed were D-Dimer, PT, aPTT, International Normalized Ratio (INR), thrombocyte, and fibrinogen. Statistical analysis was performed using the Mann-Whitney test.

Results: From the 42 confirmed COVID-19 patients, 12 patients (29%) had medium-high VTE risk and 30 patients (71%) had low. From the Mann-Whitney test, there were statistically significant differences in the D-Dimer, PT, INR, and thrombocyte value between groups of patients with medium-high and low VTE risk in patients [5.26(17.21) vs 1.54(2.61) µg/mL, p=0.004; 15.85(2.03) vs 13.40(1.40) seconds, p=0.0001; 1.18(0.30) vs 1.02(0.26), p=0.004; 160(91.50) vs 252.50(202.75) 10³/µL, p=0.003].

Conclusions: There were statistically differences in the values of D-Dimer, PT, INR, and thrombocyte between groups of patients with medium-high and low VTE risk in patients with COVID-19. The patients with medium-high risk of VTE had higher values on D-Dimer, PT, and INR tests, while lower value was found on thrombocyte.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/improve-score-and-coagulopathy-screening-in-coronavirus-disease-2019-patients/